Cargando…
PD‐L1 and PD‐L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma
Immune checkpoint inhibitors have shown efficacy in various cancers. Although programmed death ligand 1/2 (PD‐L1/L2) expressions have been demonstrated as predictive biomarkers of response to immune checkpoint inhibitors and prognostic markers, whether PD‐L1/L2 expression is altered in esophageal sq...
Autores principales: | Okadome, Kazuo, Baba, Yoshifumi, Yasuda‐Yoshihara, Noriko, Nomoto, Daichi, Yagi, Taisuke, Toihata, Tasuku, Ogawa, Katsuhiro, Sawayama, Hiroshi, Ishimoto, Takatsugu, Iwatsuki, Masaaki, Iwagami, Shiro, Miyamoto, Yuji, Yoshida, Naoya, Watanabe, Masayuki, Komohara, Yoshihiro, Baba, Hideo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819296/ https://www.ncbi.nlm.nih.gov/pubmed/34773342 http://dx.doi.org/10.1111/cas.15198 |
Ejemplares similares
-
Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers
por: Okadome, Kazuo, et al.
Publicado: (2020) -
Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer?
por: Yamashita, Kohei, et al.
Publicado: (2019) -
Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
por: Baba, Yoshifumi, et al.
Publicado: (2020) -
Primary colonic well-differentiated / dedifferentiated liposarcoma of the ascending colon: a case report
por: Sawayama, Hiroshi, et al.
Publicado: (2017) -
Immune-related adverse events and prognosis in patients with upper gastrointestinal cancer treated with nivolumab
por: Hara, Yoshihiro, et al.
Publicado: (2022)